B01AA07 - Acenocoumarol |
Propably not porphyrinogenic |
PNP |
Rationale
Acenocoumarol is metabolized by CYP 2C9, 1A2 and 2C19, but induction or inhibition of the CYP enzymes are not observed or suspected.
Chemical description
Acenocoumarol is a coumarin derivate.
Therapeutic characteristics
Acenocoumarol is a coumarin derivative and functions as vitamin K antagonist. It is used in the treatment and prevention of thromboembolic diseases.
It is administered orally and the elimination half-life from the plasma is from 8 to 11 hours.
Metabolism and pharmacokinetics
Acenocoumarol is metabolized mainly by CYP 2C9, but CYP1A2 and CYP 2C19 are also involved (Thijssen 2000, Ufer 2005).
No CYP relevant drug-drug interaction with acenocoumarol as a perpetrator has been reported in the literature (Lexi-Interact, Micromedex, SPC).
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
Thijssen HH, Flinois JP et al. Drug Metab Dispos. 2000 Nov;28(11):1284-90. |
11038154 |
| 2. | Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M. Clin Pharmacokinet. 2005;44(12):1227-46. |
16372822 |
| * | Drug interaction databases | |
| 3. | Lexi-Interact, via UpToDate.
|
|
| 4. | Micromedex® 2.0 (online). Drug Interactions). (24.05.2017).
|
|
| * | Summary of Product Characteristics | |
| 5. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC).Sinthrome.
|
|
Tradenames
Acenocoumarol 
Sintrom 
Mini-Sintrom · Sintrom 
Acenocumarol · Sintrom 
Syncumar 
Sintrom 
Sintrom · Trombostop 
Sintrom 
Acenocoumarol · Sinthrome 
Sintrom 
Sintrom 
Acenocumarol · Sintrom 
Sintrom 
Acenocumarol 
Acenokumarol 
Sintrom 
Sinthrome 
Acenocumarol 
Acenocoumarol